{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "SLN",
  "name": "Silence Therapeutics Plc",
  "url": "https://frontierpicks.com/dossiers/SLN/",
  "json_url": "https://frontierpicks.com/dossiers/SLN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Silence Therapeutics’ post-readout continuation thesis was invalidated by the 2026-09-11 weekly close of $13.02 below $13.50. Divesiran’s August clinical result remains relevant, but a renewed case requires price recovery and a disclosed development milestone.",
  "invalidation_trigger": "A weekly close below $13.50 breaks the post-readout continuation thesis at the August 2026 offering-price threshold. This condition was already met by the 2026-09-11 adjusted close of $13.02; the original case is invalidated.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "US-listed instrument is an ADS of a UK-incorporated plc; ADS economics depend on the deposit ratio and depositary fees, which differ from holding the ordinary shares.",
    "Clinical-stage developer with no approved product and no product revenue; operating cash comes from equity issuance and partner payments.",
    "No company-dated clinical readout is scheduled between 2026-09-05 and the guided 1H 2027 Phase 3 start; interim news flow is conference and partnering commentary.",
    "Zerlasiran Phase 3 timing is explicitly contingent on a third-party partner, so that program's value is event-driven rather than calendar-driven."
  ],
  "body_markdown": "## Current Thesis\n\nSilence Therapeutics’ post-readout continuation thesis has failed its published price test: the 2026-09-11 weekly close of $13.02 breached the $13.50 offering-price threshold. The underlying clinical argument remains the divesiran response reported on 2026-08-10, but that result does not reverse the market invalidation.\n\nFor this continuation leg, the narrative is dead — the September 11 close broke the condition specified in the September 5 research note. This classification concerns the market structure, not a finding that divesiran failed clinically. The remaining company argument is progression toward the guided first-half 2027 Phase 3 start, with zerlasiran development dependent on a third-party partner, according to the August 10 business update.\n\n## Bull Case\n\n- **The clinical endpoint was met.** Silence’s 2026-08-10 SANRECO release reported an 88% response with divesiran versus 19% with placebo among 48 patients with polycythemia vera. The every-12-week group recorded an 81.3% response; this supports further testing, while the sample is too small to establish uncommon-event safety or commercial success. [SANRECO release](https://silence-therapeutics.com/investors/press-releases/press-releases-details/2026/Silence-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-SANRECO-Trial-of-Divesiran-in-Polycythemia-Vera-Supporting-its-Potential-Best-in-Class-Profile/default.aspx)\n- **Financing supplied development capital.** Company pricing and closing releases reported approximately $175 million in gross proceeds from an offering priced at $13.50 per American depositary share (ADS), closed on 2026-08-14. Gross proceeds do not establish current cash or a funded-through date; neither figure is established here.\n\n## Bear Case\n\n- **The published threshold has failed.** The adjusted market series records a $13.02 close on 2026-09-11, below the $13.50 weekly condition published on September 5. The continuation case is already invalidated; a lower replacement threshold would change the original test.\n- **Cardiovascular evidence complicates the second asset.** Novartis’s 2026-09-04 filing reported that pelacarsen lowered lipoprotein(a), or Lp(a), but missed its primary cardiovascular-outcomes endpoint. Increased uncertainty for zerlasiran partnering is an inference, not a reported negotiation outcome; a disclosed partner agreement committing to Phase 3 would contradict the inference that this result obstructs development. [Novartis filing](https://www.sec.gov/Archives/edgar/data/1114448/000117184326005896/f6k_090426.htm)\n- **Full clinical disclosure remains undated.** Silence’s 2026-08-10 release promised full SANRECO results at a future medical congress without naming a presentation date. The September conference schedule therefore does not establish a new clinical-data catalyst. [SANRECO release](https://silence-therapeutics.com/investors/press-releases/press-releases-details/2026/Silence-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-SANRECO-Trial-of-Divesiran-in-Polycythemia-Vera-Supporting-its-Potential-Best-in-Class-Profile/default.aspx)\n\n## Setup & Price Structure\n\nThe supplied adjusted daily series records a 94.6% three-month price increase as of 2026-09-11, despite the close being 15.6% below the $15.43 trailing-year high. These measured figures show that a substantial preceding advance coexists with the failed $13.50 threshold. They do not establish a new support level.\n\nThe August 14 offering is observable issuance following the August 10 clinical announcement. It does not identify subsequent selling by recipients. William Blair reiterated its rating on 2026-09-10 without a numerical target listed in Stock Analysis’s analyst table, documenting continued analyst attention after the readout. Retail participation, short interest and distance above a rising moving average are not established by the available evidence, so crowding cannot be classified. [Analyst record](https://stockanalysis.com/stocks/sln/forecast/)\n\n## Catalyst Calendar (next 30 days)\n\nBoth dates come from the [company’s 2026-09-02 conference announcement](https://www.silence-therapeutics.com/investors/press-releases/press-releases-details/2026/Silence-Therapeutics-to-Participate-in-Three-September-Investor-Conferences/default.aspx). The September 9 scheduled appearance is elapsed; its content is not established here. No additional company-confirmed catalyst date in the next 30 days was verified.\n\n## Elapsed catalysts\n\n- **2026-09-15 — H.C. Wainwright conference.** Silence’s September 2 announcement schedules a fireside chat at 3:00 p.m. Eastern Time. A disclosed zerlasiran counterparty and development commitment would materially change the partnering evidence; the event announcement promises no clinical dataset. *(passed 5d ago)*\n- **2026-09-16 — Morgan Stanley conference.** The same announcement schedules a fireside chat at 8:30 a.m. Eastern Time. If both remaining appearances pass without a disclosed agreement or a dated clinical milestone, these events will not have supplied either form of confirmation. *(passed 4d ago)*\n\n## What Would Change Our Mind\n\nThe offering-price structure has already broken: a weekly close below $13.50 was the published thesis-break condition, and the 2026-09-11 close of $13.02 satisfied it. A subsequent recovery would not erase that outcome.\n\nA renewed case would require separate evidence: a weekly close above the August offering price of $13.50 together with a disclosed zerlasiran development agreement or a company-dated divesiran milestone. That conditional recovery case would fail on a subsequent weekly close below $13.50. The August 10 clinical result alone does not establish that recovery.\n\n## Correlation Notes\n\nSLN remains a single-name clinical-catalyst assessment; no synchronized peer-price series is supplied to support a group-move claim. The 2026-09-04 pelacarsen result supplies a specific link to zerlasiran through Lp(a), but it does not measure SLN’s price correlation with Novartis or Ionis and does not test divesiran’s polycythemia vera endpoint. The September 8 market headline followed the September 4 primary disclosure; it was not the trial’s announcement date. [Novartis filing](https://www.sec.gov/Archives/edgar/data/1114448/000117184326005896/f6k_090426.htm)",
  "first_seen": "2026-09-03",
  "last_analyzed": "2026-09-18T06:03:43+00:00",
  "last_synthesized": "2026-09-13",
  "last_update_source": "research_universe",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}